Atlas FDA

LIAISON XL MUREX Anti-HBc

FDA premarket approval P180038/S002 · decided 2020-08-06

Approval details

PMA number
P180038
Supplement
S002
Supplement type
Real-Time Process
Supplement reason
Change Design/Components/Specifications/Material
Trade name
LIAISON XL MUREX Anti-HBc
Generic name
Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
Applicant
DiaSorin, Inc.
Date received
2020-06-18
Decision date
2020-08-06
Days to decision
49 days
Decision code
APPR
Product code
LOM
Advisory committee
Microbiology
Expedited review
No
Location
Stillwater, MN
Statement
Approval for software version change to the LIAISON XL analyzer software.

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteX (K260770)DiaSorin, Inc.2026-06-04
LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261) (DEN250032)DiaSorin, Inc.2025-12-23
LIAISON VZV IgG HT, LIAISON Control VZV IgG HT (K231214)DiaSorin, Inc.2023-10-27
LIAISON Anti-HAV; LIAISON XS (K223403)DiaSorin, Inc.2022-12-09
LIAISON Calprotectin, LIAISON Q.S.E.T. Device Plus (K213858)DiaSorin, Inc.2022-07-26
LIAISON MeMed BV, LIAISON MeMed BV Control Set (K213936)DiaSorin, Inc.2022-07-14
LIAISON Ferritin (K193650)DiaSorin, Inc.2021-09-14
LIAISON Lyme IgM, LIAISON Lyme IgM Control Set, LIAISON Lyme Total Antibody Plus (K202573)DiaSorin, Inc.2021-02-18